<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90864">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02096653</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00092414</org_study_id>
    <nct_id>NCT02096653</nct_id>
  </id_info>
  <brief_title>Fluoroscopically-guided Versus Landmark-guided Sacroiliac Joint Injections</brief_title>
  <official_title>Randomized, Controlled, Double-blind, Comparative-effectiveness Study Comparing Fluoroscopically-guided and Landmark-guided Sacroiliac Joint Injections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Rehabilitation Sciences Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Walter Reed National Military Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators are attempting to determine whether intra- or
      extra-articular injections are more effective; the relative prevalence rate of
      intra-articular and extra-articular SI joint pain; and the accuracy of extra-articular
      injections using fluoroscopy as the reference standard. 124 consecutive patients with
      mechanical low back pain below L5, tenderness overlying the SI joint(s) and at least 3
      positive provocative maneuvers will be randomized to receive SI joint injections by 2
      different approaches.

      Group 1 will receive fluoroscopically-guided injections into the joint.  Group 2 will
      receive landmark-guided injections into the tender area around the joint.  In order to
      determine whether the injection in group 2 was intra-articular or extra-articular, an x-ray
      will be done after the injection to ascertain the location of contrast spread.  The primary
      outcome measure will be pain relief at 1-month.  Patients who obtain benefit at 1-month will
      be followed at 3-months, while those who fail to obtain benefit will exit the study to
      receive alternative care.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pain score</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>0-10 numerical rating scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oswestry disability index score</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measure of function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>0-10 numerical rating scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oswestry disability index</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measure of function</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Sacroiliac Joint Pain</condition>
  <arm_group>
    <arm_group_label>Fluoroscopically-guided intra-articular injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of 40 mg depomethylprednisolone and 2 ml 0.5% bupivacaine into the sacroiliac joint cavity under fluoroscopic guidance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Landmark-guided sacroiliac joint injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection of 40 mg depomethylprednisolone and 2 ml 0.5% bupivacaine at the point of maximal tenderness (3 ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intra-articular sacroiliac joint steroid injection (depomethylprednisolone and bupivacaine)</intervention_name>
    <description>Injection of steroid and local anesthetic into the joint cavity using fluoroscopic guidance</description>
    <arm_group_label>Fluoroscopically-guided intra-articular injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Landmark guided sacroiliac joint steroid injection (depomethylprednisolone and bupivacaine)</intervention_name>
    <description>Injection of steroid into the joint area based on palpation.  The injection may be inside the joint (intra-articular) or outside the joint in the ligaments (extra-articular)</description>
    <arm_group_label>Landmark-guided sacroiliac joint injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 18;

          2. Low back pain principally below the L5 vertebra;

          3. Three out of 6 positive SI joint provocative maneuvers;

          4. Agreed to undergo SI joint injection for diagnostic/ therapeutic purposes;

          5. Average pain score &gt; 4/10 over the past week;

          6. Pain duration &gt; 6 weeks;

        Exclusion Criteria:

          1. Previous SI joint injection;

          2. Leg pain &gt; back pain or lower leg pain &gt; upper leg pain

          3. Active inflammatory spondyloarthropathy (e.g. ankylosing spondylitis);

          4. Untreated coagulopathy;

          5. Allergy to contrast dye or bupivacaine;

          6. Pain &gt; 10 years in duration;

          7. Poorly controlled psychiatric (e.g. PTSD) or medical (congestive heart failure)
             condition
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Steven P Cohen, MD</last_name>
    <phone>4109551818</phone>
    <email>scohen40@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven P Cohen, MD</last_name>
      <phone>410-955-1818</phone>
      <email>scohen40@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Steven P Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Connie Kurihara, RN</last_name>
      <phone>301-400-2595</phone>
      <email>conniekurihara@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Scott R Griffith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cohen SP, Chen Y, Neufeld NJ. Sacroiliac joint pain: a comprehensive review of epidemiology, diagnosis and treatment. Expert Rev Neurother. 2013 Jan;13(1):99-116. doi: 10.1586/ern.12.148. Review.</citation>
    <PMID>23253394</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>March 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Steven P. Cohen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>sacroiliac joint pain</keyword>
  <keyword>low back pain</keyword>
  <keyword>steroid injection</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
